Financial Performance - Q3'25 total revenues were $995.7 million, up 1.8% year-over-year and down 1.7% sequentially, exceeding guidance of $965 million to $985 million[2] - Q3'25 diluted net income per share was $0.78, while non-GAAP diluted net income per share was $2.61, representing a 7.6% year-over-year increase[4] - Net revenues for Q3 2025 were $995.7 million, a 1% increase from $977.9 million in Q3 2024[27] - Gross profit for Q3 2025 was $639.2 million, down 6.2% from $681.8 million in Q3 2024[27] - Operating expenses totaled $542.9 million in Q3 2025, compared to $519.5 million in Q3 2024, reflecting a 4.5% increase[27] - Net income for Q3 2025 was $56.8 million, a decrease of 51% from $116.0 million in Q3 2024[27] - Basic net income per share for Q3 2025 was $0.78, down from $1.55 in Q3 2024[27] - GAAP net revenues for Q3 2025 were $995,692, reflecting a constant currency impact decrease of $11,680 or 1.2% from Q2 2025[32] - GAAP gross profit for Q3 2025 was $639,201, with a gross margin of 64.2%, down from 69.9% in Q2 2025[34] - GAAP income from operations for Q3 2025 was $96,298, resulting in an operating margin of 9.7%, down from 16.1% in Q2 2025[35] - Non-GAAP gross profit for Q3 2025 was $701,099,000, compared to $688,546,000 in Q3 2024, reflecting an increase of 1.6%[36] - Non-GAAP net income for Q3 2025 was $188,988,000, compared to $175,622,000 in Q3 2024, an increase of 7.8%[37] - GAAP operating margin for Q3 2025 was 9.7%, down from 16.6% in Q3 2024[36] - Non-GAAP operating margin for Q3 2025 was 23.9%, compared to 22.1% in Q3 2024, indicating an improvement of 1.8 percentage points[36] Cash and Investments - Cash and cash equivalents as of September 30, 2025, were $1,004.6 million, up from $901.2 million as of June 30, 2025[6] - Cash, cash equivalents, and restricted cash at the end of the period were $1,005,808, down from $1,042,981 at the end of the previous year[29] - Net cash provided by operating activities decreased to $370,046, down 18.2% from $452,153 in the same period last year[29] - Net cash used in investing activities was $76,529, a significant reduction from $200,996 in the previous year[29] Shareholder Actions - During Q3'25, approximately 0.5 million shares were repurchased at an average price of $136.77 per share, as part of a $200 million repurchase plan[8] Future Projections - Q4'25 worldwide revenues are expected to be in the range of $1,025 million to $1,045 million, indicating sequential growth from Q3'25[13] - Q4'25 non-GAAP operating margin is projected to be approximately 26.0%, up sequentially from Q3'25[15] - The company expects fiscal 2025 Clear Aligner volume growth to be mid-single digits, with revenue growth flat to slightly up from 2024[15] - The company expects growth in Clear Aligner volume and revenue for fiscal year 2025[23] - The company expects Q4 2025 GAAP gross margin to be between 65.5% and 66.0%[40] - For fiscal 2025, the company anticipates a GAAP operating margin of 13.6% to 13.8%[41] - The expected non-GAAP operating margin for fiscal 2025 is approximately 22.5%[41] Product Developments - Q3'25 Clear Aligner revenues were $805.8 million, up 2.4% year-over-year and up 0.1% sequentially, with volume at 647.8 thousand cases, reflecting a 4.9% year-over-year increase[3] - Align Technology announced the ClinCheck Live Plan, a new feature that automates treatment planning within 15 minutes, significantly reducing the planning cycle[7] - Clear Aligner revenue per case shipment in Q3 2025 was $1,245, a decrease from $1,250 in Q2 2025[30] - The number of Invisalign trained doctors receiving cases in Q3 2025 was 88,155, showing a slight increase from 87,380 in Q2 2025[30] Legal Matters - Align Technology filed a complaint against Angelalign Technology, alleging patent infringement related to clear aligners[7] Asset Management - Total assets as of September 30, 2025, were $6.23 billion, slightly up from $6.21 billion at the end of 2024[28] - Accounts receivable increased to $1.10 billion from $995.7 million at the end of 2024[28] - Cash and cash equivalents decreased to $1.00 billion from $1.04 billion at the end of 2024[28] Research and Development - Align Technology continues to invest in research and development, with expenses rising to $93.3 million in Q3 2025 from $85.3 million in Q3 2024[27]

Shares of Align Technology (ALGN) are up 0.30% today, but the real action is happening off the tape. ...

Group 1 - The portfolio's stock selection faced broad negative performance across sectors in Q3, indicating significant headwinds affecting overall results [2][3] - The commentary highlights that the negative stock selection was a major contributor to the portfolio's underperformance relative to benchmarks [3] - The report suggests that the challenges faced in Q3 were reflective of broader market conditions impacting various sectors [3]

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Align Technology, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][2] Investigation Details - The investigation centers on whether Align issued false or misleading statements and failed to disclose critical information to investors [2] - Align's Q2 2025 financial results, announced on July 30, 2025, missed both analyst expectations and the company's own revenue guidance, leading to a significant drop in share price by nearly 37% the following day [2] Next Steps - Investors who purchased Align shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various complex litigations across state and federal courts [4]

Group 1 - Align Technology (NASDAQ: ALGN) is rated as a hold due to poor results in recent quarters despite being a high-quality business prior to the COVID-19 scenario [1] - The company faces competition from emerging brands, which may impact its market position [1] Group 2 - The analysis emphasizes a long-term investment approach, focusing on price and margin of safety while considering risks often overlooked by short-term analysts [1]

Market Overview - Major indices experienced their third consecutive day of declines, with the Dow Jones Industrial Average down 0.3% to 46,121.28, the S&P 500 down 0.6% to 6,637.97, and the Nasdaq Composite down 0.9% to 22,497.86, attributed to profit-taking in the tech sector and concerns over high valuations [1][2] Automotive Industry - The Trump administration cut tariffs on EU automotive imports from 25% to 15%, effective August 1, leading to a rise in European automaker shares, with Porsche up 3.8% and other German manufacturers also seeing gains [3] - Earlier threats of a 25% tariff had negatively impacted shares of Volkswagen, BMW, and Porsche, which saw declines of 1.26%, 2.21%, and 2.51% respectively [3] Medical Device Sector - The U.S. Commerce Department announced new investigations into imports of medical devices, potentially leading to higher tariffs, which caused shares of major medical device manufacturers to drop, with Baxter International down 3.5%, GE HealthCare down 5.3%, and Integra LifeSciences down 5.3% [4] - Analysts described this situation as a new overhang for the medical device sector, with JPMorgan advising against panic [4] IT Sector - A new H-1B visa fee of $100,000 per visa has been implemented, significantly impacting Indian IT stocks, with the Nifty IT index falling over 6% this week and major firms like Tata Consultancy Services and Infosys experiencing declines of 2.7% and 2.58% respectively [5] - Analysts suggest a limited earnings impact for larger firms but highlight potential issues for U.S. health systems due to the upfront costs associated with the new visa fees [5] Pharmaceutical Industry - The threat of a 200% tariff on imported drugs has caused significant declines in global pharma shares, with U.S. companies like Amgen, AbbVie, and Pfizer dropping between 3% and 6% [6][7] - In response to tariff threats, major drugmakers are announcing substantial investments in U.S. production, with Johnson & Johnson committing $55 billion, Roche $50 billion, and GSK $30 billion [7] Geopolitical Developments - President Trump is expected to sign a deal allowing the sale of TikTok's U.S. operations to American investors, which has led to volatility in Oracle's stock, reflecting the market's interest in tech diplomacy [8] - Discussions with Turkish President Erdogan included the potential purchase of Boeing aircraft, with Boeing's stock having increased 46.5% over the last five years [9]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Align Technology, Inc. and its officers or directors, following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - Align Technology reported total revenues of approximately $1.01 billion for Q2 2025, which was below both consensus estimates and the company's own guidance [3]. - The company lowered its revenue guidance for Q3 and full-year growth expectations, attributing this to economic uncertainty and reduced demand for its products [3]. - Following the announcement, Align's stock price fell by $74.56 per share, or 36.63%, closing at $129.01 per share on July 31, 2025 [3]. Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of investors regarding potential securities fraud by Align Technology [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the investigation and potential class action [1].

Core Viewpoint - The article emphasizes the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article suggests that users may face access issues if they have an ad-blocker enabled [1] - It highlights the need to disable ad-blockers and refresh the page for a better experience [1]

Core Viewpoint - Align Technology, Inc. has filed a complaint under Section 337 of the Tariff Act, addressing issues of unfair competition related to the importation and sale of goods [1] Company Overview - Align Technology is a leading global medical device company specializing in the design, manufacture, and sale of the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry [1]

Company Overview - Align Technology is a leading manufacturer in the global orthodontics market, which is valued at $6.5 billion, primarily known for its Invisalign system of clear aligners [1]. Leadership Presentation - The presentation features key executives including Chief Financial Officer John Morici and Vice President of Finance, Corporate and Investor Communications Shirley Stacy, indicating a strong leadership presence [2].